ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The discovery of the pathophysiology of chronic myeloid leukemia (CML) made possible to design drugs focused on a molecular target (BCR::ABL1), opening a new era in anti-tumor therapy through tyrosine kinase inhibitors (TKIs) [1].